Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bimatoprost + brimonidine tartrate + timolol
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
A fixed-dose ophthalmic combination of three agents—bimatoprost (a prostaglandin analog), brimonidine tartrate (an alpha-2 adrenergic agonist), and timolol (a non-selective beta-adrenergic blocker)—used to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. This triple fixed combination is designed for patients whose IOP is not adequately controlled with dual-combination therapy. Bimatoprost increases aqueous humor outflow via the uveoscleral pathway; brimonidine decreases aqueous humor production and increases uveoscleral outflow; timolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary body. The product has demonstrated superior efficacy over dual combinations and is approved in several countries including Brazil, Chile, Colombia, Ecuador, and Mexico[1][3][6].
- Other names
- bimatoprost + brimonidine tartrate + timololtriple fixed combination bimatoprost/brimonidine/timololTFC
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)ADRA2A (α2A)ADRB1 (β1)
Beyond the preview
Go deeper on bimatoprost + brimonidine tartrate + timolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bimatoprost + brimonidine tartrate + timolol.